Stocks to Watch: Gemini Explorations, Inc. (OTC BB:GXPI.OB), Western Standard Energy Corp. (OTC BB:WSEG.OB) , Bionovo, Inc. (NasdaqCM:BNVI) , Osteologix Inc. (OTC BB:OLGX.OB) , Stoneridge Inc. (NYSE:SRI)
Featured Stock: Gemini Explorations, Inc.
(OTC BB:GXPI)
Current Price (0.10)
http://www.wallstreetstockreview.com/
GEMINI EXPLORATIONS INC INCREASES PROJECTED CASH FLOW OF THE LOS CHORROS GOLD MINE
~Mine modernization projected to yield US$12,960,000 of net cash flow to Gemini~
The Los Chorros Mine is currently being mined with extremely antiquated equipment and this report further solidifies Gemini’s belief that the project could be turned into a highly efficient producing gold project with low capital costs. Current mining operations at Los Chorros recover a low percentage of the available gold and precious metals present on the property. The plant would initially run at 30 to 50 tonnes/day with a targeted production rate of 100 tonnes per day during the first year. The total cost of the project is estimated to be US$595,900, adding a contingency factor of 30% would bring the maximum projected total to US$774,700.The reports were prepared by general manager Juan Fernando Restrepo and chief geologist Carlos Alberto Vera of Minera Primecap Geological Services (MPGS) of
Historically one of the largest gold producing countries in the world,
Notice Regarding Forward Looking Statements
This news release contains "forward-looking statements", as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the expectation of the gold production of the property, the expected completion date of the redevelopment and modernization of the Los Chorros Gold mine and the low capital costs to upgrade the Los Chorros operating plant and the net cash flow estimates.Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with mineral exploration. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-KSB for the 2006 fiscal year, our quarterly reports on Form 10-QSB and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
Michael Hill
President
Gemini Explorations, Inc
http://www.geminiexploration.com/ email: info@geminiexploration.com
IR info: 1 877 700 1644
For an in-depth analyst report, please visit : http://www.wallstreetstockreview.com/
Western Standard Energy Corp.
(OTC BB:WSEG.OB)
Current Price (.50)
Bionovo, Inc.
(NasdaqCM:BNVI)
Current Price (2.33)
EMERYVILLE, Calif., Nov. 1-- Bionovo, Inc. (Nasdaq: BNVI - News), a leader in the discovery and development of safe and effective drugs in the areas of women's health and cancer, is scheduled to present at the 9th Annual Acumen BioFin Rodman and Renshaw Healthcare Conference in New York. The presentation by Tom Chesterman, SVP and CFO of Bionovo, Inc., will take place on November 6, 2007 at 4:45 p.m. local time at the New York Palace Hotel in
Osteologix Inc.
(OTC BB:OLGX.OB)
Current Price (1.50)
SAN FRANCISCO--Nov.1--Osteologix Inc. (OTCBB:OLGX - News), a specialty pharmaceutical company, today announced that Malene Weis M.SC.Pharm., Director of Clinical Development of Osteologix, will give a presentation entitled “Challenges for Small Pharma in Setting up and Managing a Clinical Trial” during a Symposium regarding outsourcing challenges for small pharma and biotech at the 6th Annual Partnerships in Clinical Trials Congress and Exhibition 2007 on Monday, November 5, 2007 in Amsterdam RAI, The Netherlands. Following her presentation, Weis will participate as a panel member during the Discussion Session entitled “Developing an Outsourcing Strategy that Keeps Pace with Your Company’s Growth”. Weis has worked with all stages of clinical development at both pharmaceutical companies and contract research organizations (CROs). She has held prime responsibility for the design and operational execution of numerous clinical trials within various therapeutic areas, including Osteologix’s latest Phase II STRONG Study of the company’s lead drug candidate for the treatment and prevention of osteoporosis, NB S101. The data for the STRONG Study will be released in the 4th quarter of 2007. Osteologix is a specialty pharmaceutical company committed to developing innovative therapies for the treatment and prevention of musculoskeletal diseases. The Company’s vision is to improve the health of those afflicted with musculoskeletal diseases such as osteoporosis. Its lead product candidate, NB S101, is a novel pharmaceutical agent for the treatment and prevention of osteoporosis. For more information please visit www.osteologix.com.
Stoneridge Inc.
(NYSE:SRI)
Current Price (10.16)
WARREN,
WallStreetStockReview.com is owned and operated by Iron Consulting.
Verify all claims and do your own due diligence. Iron Consulting profiles are not a solicitation or recommendation to buy, sell or hold securities. Iron Consulting is not offering secu rities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. Iron Consulting is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b),WallStreetStockReview.com is owned and operated by Iron Consulting. Iron Consulting www.ironconsultinginc.com has receive seventy two thousand dollars in 2006 and thirty six thousand in 2007 from Equity Alliance Intl. www.equityallianceir.com for a internet marketing program. Neither Iron Consulting nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since Iron Consulting receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in Iron Consulting statements and opinions and such statements and opinions cannot be considered independent. Iron Consulting and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements ar e made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Iron Consulting services are often paid for using free-trading shares. Iron Consulting may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.
